Cite
PCN25 Systematic Literature Review of Treatment Patterns, Long-Term Efficacy, and Safety of Dasatinib Therapy for Patients with Chronic Myeloid Leukemia
MLA
A. Kee, et al. “PCN25 Systematic Literature Review of Treatment Patterns, Long-Term Efficacy, and Safety of Dasatinib Therapy for Patients with Chronic Myeloid Leukemia.” Value in Health, vol. 24, June 2021, p. S23. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........70658c7ffc2fbaff7c7d1b37f3156ff0&authtype=sso&custid=ns315887.
APA
A. Kee, S. Harricharan, Anna Forsythe, Ronda Copher, J. Brokars, & S. Grieve. (2021). PCN25 Systematic Literature Review of Treatment Patterns, Long-Term Efficacy, and Safety of Dasatinib Therapy for Patients with Chronic Myeloid Leukemia. Value in Health, 24, S23.
Chicago
A. Kee, S. Harricharan, Anna Forsythe, Ronda Copher, J. Brokars, and S. Grieve. 2021. “PCN25 Systematic Literature Review of Treatment Patterns, Long-Term Efficacy, and Safety of Dasatinib Therapy for Patients with Chronic Myeloid Leukemia.” Value in Health 24 (June): S23. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........70658c7ffc2fbaff7c7d1b37f3156ff0&authtype=sso&custid=ns315887.